Pcv6 - Sacubitril/Valsartan in Heart Failure: Projected Health Outcomes in Portugal

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.553
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Sacubitril-Valsartan in Heart Failure and Multimorbidity Patients

ESC heart failure
Cardiovascular MedicineCardiology
2018English

Reply: Sacubitril/Valsartan for Chagas' Heart Disease Heart Failure?

ESC heart failure
Cardiovascular MedicineCardiology
2018English

Perceived Barriers to Sacubitril/Valsartan Use in Patients With Heart Failure

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2018English

Cost-Effectiveness of Sacubitril/Valsartan in the Treatment of Heart Failure in Colombia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Pcv71 - Cost-Effectiveness of Sacubitril/Valsartan for the Treatment of Symptomatic Chronic Heart Failure With Reduced Ejection Fraction in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Safety of Initiation of Sacubitril/Valsartan in ICU Patients With Advanced Decompensated Heart Failure

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Profile of Sacubitril/Valsartan in the Treatment of Heart Failure: Patient Selection and Perspectives

Vascular Health and Risk Management
2017English

The Reverse Remodeling Response to Sacubitril/Valsartan Therapy in Heart Failure With Reduced Ejection Fraction

Cardiovascular Therapeutics
MedicineCardiovascular MedicinePharmacologyCardiology
2018English

Sacubitril/Valsartan Associated With Lower Declines in Health-Related Quality of Life Compared With Enalapril in Patients With Heart Failure Hospitalization

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy